A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine nasal spray (Spravato) monotherapy ...

In such cases, patients may be prescribed neuromodulation therapy, which modulates brain activity in order to reduce ...

Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. See why I rate ...

FOR decades, Sarah Smith suffered with depression. But now, due to a futuristic-looking headset that zapped electronic pulses deep into her brain, her fog has lifted. She tells Sun Health: “It’s ...

Compass Pathways plc has exciting developments in treating treatment-resistant depression with the innovative COMP360. Click ...

In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials ...

Compass Pathways’ journey to phase 3 psychedelic depression data is taking longer than expected. | Compass Pathways’ journey to phase 3 psychedelic depression data is taking longer than expected. With ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of ...

Depression often causes people to view daily life negatively, a bias linked to specific changes in brain circuits.

Ultrasound is already used for diagnosis and therapy. Recent studies have found it also to be a safe, effective, and rapid ...

State lawmakers are considering a bill that would legalize production and use of psilocybin as a mental health treatment in ...